Correlation of the intrinsic clearance of donepezil (Aricept®) between in vivo and in vitro studies in rat, dog and human

References

• BAARNH1ELM, C., DAHLBACK, H. and SKANBERG, I., 1986, In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacologica et Toxologica, 59, 113–122.
   Google Scholar
• BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmacology, 8, 165–176.
   PubMedGoogle Scholar
• CHIBA, M., FuTrTA, S. and Suzum, T., 1990a, Kinetic properties of the metabolism of imipramine and despramine in isolated rat hepatocytes. Biochemical Pharmacology, 39, 367–372.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., FuTrTA, S. and Suzum, T., 1990b, Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and despramine in rats. Journal of Pharmaceutical Science, 79, 281–287.
   PubMed Web of Science ®Google Scholar
• DEDRICK, R. L., ZAHARKO, D. S. and LUTZ, R. L., 1973, Transport and binding of methotrexate in vivo. Journal of Pharmaceutical Science, 62, 882–890.
   PubMed Web of Science ®Google Scholar
• GILLETTE, J. R., 1984, Problems in correlating in vitro and in vivo studies of drug metabolism. In L. Z. Benet G. Levy and B. L. Ferraiole (eds), Pharmacokinetics: A Modem View (New York: Plenum), pp. 235–252.
   Google Scholar
• HANANO M., SAWADA, Y., IGA, T. and SUGIYAMA, Y., 1987, The integration of in vitro data with physiological data. In D. D. Brimer and P. Speeder (eds), Topics in Pharmaceutical Science (Amsterdam: Elsevier), pp. 63–77.
   Google Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
   PubMed Web of Science ®Google Scholar
• JoLY, J. G., DOYON C. and PESANT Y, 1975, Cytochrome P450 measurement in rat liver homogenate and microsomes. Its use for correction of micros omal losses incurred by differential centrifugation. Drug Metabolism and Disposition, 3, 577–586.
   Google Scholar
• KAMATAKI, T., 1974, Effect of lypophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Journal of Pharmacology, 24, 195–203.
   Google Scholar
• LIN, J. H., HAYASHI, M., AWAZU, S. and HANANO, M., 1978, Correlation between in vitro and in vivo drug metabolism rate: Oxidation of ethoxybenzamide in rat. Journal of Pharmacokinetics and Biopharmacology, 6, 327–337.
   PubMedGoogle Scholar
• LE.T, J. H., SUGIYAMA, Y., AWAZU, S. and HANANO, M., 1982, Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. Journal of Pharmacokinetics and Biopharmacology, 10, 649–661.
   Google Scholar
• LOWRY, O. H., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MATSUI, K. and MISHEVIA, M., 1999, Absorption, distribution, metabolism and excretion of donepezil (Aricepto) after a single oral administration (in preparation).
   Google Scholar
• PANG, K. S. and CHIBA, M., 1994, Metabolism: scaling-up from in vitro to organ and whole body. In P. C. Welling and L. P. Balant (eds), Handbook of Experimental Pharmacology (New York: Springer), pp. 101–187.
   Google Scholar
• PANG, K. S. and ROWLAND, M., 1977, Hepatic clearance of drugs. III. Additional experimental evidence supporting the 'well-stirred' model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. Journal of Pharmacokinetics and Biopharmacology, 5, 681–699.
   PubMedGoogle Scholar
• RHO, J. P. and LIPSON, L. G., 1997, Formulary, 32, 7.
   Google Scholar
• ROBERTS, M. S. and ROWLAND, M., 1986a, A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmacology, 14, 227–260.
   PubMedGoogle Scholar
• ROBERTS, M. S. and ROWLAND, M., 1986b, A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. Journal of Pharmacokinetics and Biopharmacology, 14, 289–308.
   PubMedGoogle Scholar
• ROBINSON, P. J., BASS, L., POND, S. M., ROBERTS, M. S. and WAGNER, J. G., 1988, Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients. Journal of Pharmacokinetics and Biopharmacology, 16, 229–249.
   PubMedGoogle Scholar
• ROGERS, S. L., DOODY, R. S., Moxs, R. C. and FRIEDHOFF, L. T., 1998, Archives of Internal Medicine, 158, 1021.
   Google Scholar
• ROWLAND, M., BENET, L. Z. and GRAHAM, G. G., 1973, Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology, 1, 123–136.
   PubMedGoogle Scholar
• SUGIYAMA, Y., SAWADA, Y., IGA, T. and HANANO, M., 1989, Reconstruction of in vivo metabolism from in vitro data. In R. Kato, I. LW. Estabrook and M. N. Cayen (eds), Xenobiotic Metabolism and Disposition (London: Taylor & Francis), pp. 225–235.
   Google Scholar
• WILKINSON, G. R., 1987, Clearance approaches in pharmacology. Pharmacology Reviews, 39, 1-47. WILKINSON, G. R. and SHAND, D. G., 1975, Commentary: a physiological approach to hepatic drug clearance. Clinical Pharmacology, 18, 377–390.
   Google Scholar
• YAMANISHI, Y., 1990, Basic clinical and therapeutic aspect of Alzheimer's and Parkinson's diseases, 2, 409.
   Google Scholar
• YAMAOKA, K., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879–885.
   PubMedGoogle Scholar